Skip to main content

Table 1 Demographics of survey respondents

From: Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE

 

Pediatric nephrologists

Pediatric rheumatologists

Total Respondents

N = 76a

N = 41a

Medical Centers

N = 56

N = 15

Peds Neph Board-Eligible

100%

0%

Peds Rheum Board-Eligible

0%

100%

Years in Practice

 < 2

2%

7%

 2–5

29%

17%

 6–10

25%

17%

 > 10

45%

60%

# of Pediatric SLE Patients

 0–25

52%

37%

 25–50

14%

20%

 50–100

19%

30%

 > 100

6%

13%

LN Standard Protocol

51%

24%

  1. aApproximately 15% of ASPN and CARRA membership
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096